<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01246388</url>
  </required_header>
  <id_info>
    <org_study_id>LU-TI-01</org_study_id>
    <nct_id>NCT01246388</nct_id>
  </id_info>
  <brief_title>Non-Invasive Evaluation of Fibrosis and Steatosis in Chronic Hepatopathy</brief_title>
  <official_title>Evaluation of Fibrosis and Steatosis in Patients With Chronic Hepatopathy: Non-invasive Imaging and Serum Markers vs. Liver Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tischendorf, Jens, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tischendorf, Jens, M.D.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate non-invasive parameters for staging and grading of
      chronic hepatopathy in comparison to liver biopsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For diagnosis, staging and grading of chronic liver disease, liver biopsy is the gold
      standard to date. Unfortunately, being an invasive diagnostic method, liver biopsy has a
      significant morbidity. Furthermore, due to the small sample size, sampling error (over- or
      underestimating severity of liver disease) is a serious problem in diagnostic of chronic
      liver disease.

      The objective of this study is to evaluate non-invasive diagnostic methods (MRI,
      elastography, ultrasound and serum parameters) in comparison to the gold standard to
      establish criteria for diagnostic in liver disease and reduce the necessary amount of liver
      biopsies in the future and allow regular follow up.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of staging fibrosis (METAVIR scoring system) with a combination of MRT and blood serum markers compared to liver biopsy (gold standard)</measure>
    <time_frame>singular evaluation at the time of liver biopsy (completion of measurements within 2 days before or after liver biopsy)</time_frame>
    <description>Receiver operating characteristic analysis is performed (Area-under-the-ROC-curve) to evaluate non-invasive fibrosis assessment in comparison to the liver biopsy with SPSS-Software, p &lt; 0,05 is regarded as statistically significant. METAVIR is a 5-point scale used in staging fibrosis (0 = no fibrosis, 4 = high grade fibrosis, cirrhosis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of staging steatosis (four-graded scale, percentage) with a combination of MRT and blood serum markers compared to liver biopsy (gold standard)</measure>
    <time_frame>singular evaluation at the time of liver biopsy (completion of measurements within 2 days before or after liver biopsy)</time_frame>
    <description>Receiver operating characteristic analysis is performed (Area-under-the-ROC-curve) to evaluate non-invasive steatosis assessment (MR-spectroscopy, ultrasound)in comparison to the liver biopsy with SPSS-Software, p &lt; 0,05 is regarded as statistically significant. The degree of steatosis in liver biopsies and ultrasound is assessed by a morphological semiquantitative approach: 0: none, 1: slight, 2: moderate and 3: severe.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Liver Disease</condition>
  <condition>Steatohepatitis</condition>
  <condition>Fibrosis</condition>
  <arm_group>
    <arm_group_label>Chronic Liver Disease</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        in- and outclinic patients of the RTWH University Hospital (Department of Medicine III)
        with chronic hepatopathy and the necessity of undergoing liver biopsy for diagnostic work
        up
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic hepatopathy and necessity of liver biopsy

        Exclusion Criteria:

          -  metal implants preventing MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holger H Lutz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine III, University Hospital RTWH University of Aachen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Medicine III, University Hospital Aachen (RWTH)</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat. 2009 May;16(5):300-14. doi: 10.1111/j.1365-2893.2009.01087.x. Epub 2009 Feb 25. Review.</citation>
    <PMID>19254351</PMID>
  </reference>
  <reference>
    <citation>Bonekamp S, Kamel I, Solga S, Clark J. Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately? J Hepatol. 2009 Jan;50(1):17-35. doi: 10.1016/j.jhep.2008.10.016. Epub 2008 Nov 8. Review.</citation>
    <PMID>19022517</PMID>
  </reference>
  <reference>
    <citation>Faria SC, Ganesan K, Mwangi I, Shiehmorteza M, Viamonte B, Mazhar S, Peterson M, Kono Y, Santillan C, Casola G, Sirlin CB. MR imaging of liver fibrosis: current state of the art. Radiographics. 2009 Oct;29(6):1615-35. doi: 10.1148/rg.296095512. Review.</citation>
    <PMID>19959511</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2010</study_first_submitted>
  <study_first_submitted_qc>November 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2010</study_first_posted>
  <last_update_submitted>October 19, 2014</last_update_submitted>
  <last_update_submitted_qc>October 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fibrosis</keyword>
  <keyword>Steatosis</keyword>
  <keyword>Liver biopsy</keyword>
  <keyword>Elastography</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

